Alapfogalmak
Noninvasive testing is crucial for NAFLD patients' management and monitoring.
Kivonat
Noninvasive testing is highlighted as a vital tool for risk stratification and monitoring of NAFLD patients, offering a safer alternative to biopsies. The Clinical Practice Update Expert Review by the American Gastroenterological Association emphasizes the importance of noninvasive testing in enhancing patient care by detecting advanced fibrosis early. The update provides best practice advice for the optimal use of noninvasive tests in NAFLD patients, aiming to improve outcomes and facilitate timely clinical management. Key points include the recommendation to use various noninvasive tests for risk stratification, the importance of interpreting results in the context of clinical data, and the need for longitudinal monitoring to guide treatment decisions.
Statisztikák
"The health care burden of longitudinal management of patients with NAFLD is significant."
"The emergence and utilization of noninvasive testing (NIT) in gastroenterology practices has the potential to significantly enhance the care of patients with NAFLD."
"The first statement encourages use of NITs for risk stratification during the diagnosis of NAFLD."
"Second, the update suggests that patients with a FIB-4 less than 1.3 are unlikely to have advanced hepatic fibrosis."
"The fourth piece of best-practice advice suggests that clinicians follow manufacturer's specifications when implementing NITs."
"The penultimate best practice advice suggests use of NITs for serial longitudinal disease monitoring."
Idézetek
"The health care burden of longitudinal management of patients with NAFLD is significant."
"The emergence and utilization of noninvasive testing (NIT) in gastroenterology practices has the potential to significantly enhance the care of patients with NAFLD."